Kawasaki Disease Clinical Trial
Official title:
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery abnormalities that may lead to complications later in life, including heart attack. Although the investigators can identify children with KD that have these coronary artery abnormalities, there is no approved additional treatment to decrease coronary artery inflammation and arrest or prevent damage to the coronary arteries. Anakinra, a therapy that blocks the high levels of interleukin 1 (IL1) that lead to inflammation during acute KD, has been shown in the KD mouse model to prevent the development of coronary artery damage. Therefore, the investigators propose to study the safety and activity of anakinra in infants and children < 2 years old with coronary artery abnormalities from KD.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05911386 -
Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
|
||
| Recruiting |
NCT02951234 -
A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease
|
N/A | |
| Active, not recruiting |
NCT02853266 -
Measurement of Antibodies in Adults With a History of Kawasaki Disease
|
N/A | |
| Active, not recruiting |
NCT04747847 -
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
|
Early Phase 1 | |
| Withdrawn |
NCT04535518 -
Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
|
Phase 3 | |
| Recruiting |
NCT01917721 -
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
|
Phase 2 | |
| Recruiting |
NCT04656184 -
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
|
Phase 3 | |
| Recruiting |
NCT03200561 -
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
|
Phase 3 | |
| Completed |
NCT01440075 -
Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease
|
N/A | |
| Withdrawn |
NCT02980263 -
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
|
Phase 2 | |
| Enrolling by invitation |
NCT02359643 -
Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease
|
N/A | |
| Recruiting |
NCT04278404 -
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
|
||
| Completed |
NCT00841789 -
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
|
Phase 2 | |
| Completed |
NCT00760435 -
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
|
Phase 3 | |
| Not yet recruiting |
NCT05643651 -
Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease
|
Phase 4 | |
| Recruiting |
NCT02114099 -
Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease
|
Phase 2 | |
| Not yet recruiting |
NCT05091229 -
A Blood Test to Diagnose Kawasaki Disease
|
||
| Completed |
NCT01431105 -
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Recruiting |
NCT06305611 -
European and North Indian Cohort of KaWasaki dIsease
|